Skip to main content

Stemline Therapeutics to be Acquired by Menarini Group

Former TAP Partner


FLORENCE, Italy and NEW YORK, May 04, 2020 (GLOBE NEWSWIRE) -- Menarini Group, a privately held Italian pharmaceutical and diagnostics company, and Stemline Therapeutics Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, (Nasdaq: STML) today announced a definitive agreement under which Menarini Group will acquire Stemline in a transaction valued up to $677 million.

ELZONRIS® (tagraxofusp), a targeted therapy directed to CD123, is approved by the U.S. Food and Drug Administration (FDA) and commercially available in the U.S. for the treatment of adult and pediatric patients, two years or older, with BPDCN. For full prescribing information in the U.S., visit In Europe, a marketing authorization application (MAA) is under review by the European Medicines Agency (EMA). The study (NCT02113982) that led to approval by the FDA was supported in part by The Leukemia & Lymphoma Society's Therapy Acceleration Program® (TAP). This is the third approval for a TAP supported project.